

OIPE

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/825,242

DATE: 04/25/2001

TIME: 13:49:23

Input Set : N:\Crf3\RULE60\09825242.txt

Output Set: N:\CRF3\04252001\I825242.raw

3 <110> APPLICANT: Schenk, Dale B.  
 4 Neuralab Limited  
 6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
 8 <130> FILE REFERENCE: 15270J-004720US  
 10 <140> CURRENT APPLICATION NUMBER: 09/825,242  
 11 <141> CURRENT FILING DATE: 2001-04-02  
 13 <150> PRIOR APPLICATION NUMBER: 09/201,430  
 14 <151> PRIOR FILING DATE: 1998-11-30  
 16 <150> PRIOR APPLICATION NUMBER: US 60/080,970  
 17 <151> PRIOR FILING DATE: 1998-04-07  
 19 <160> NUMBER OF SEQ ID NOS: 5  
 21 <170> SOFTWARE: PatentIn Ver. 2.1  
 23 <210> SEQ ID NO: 1  
 24 <211> LENGTH: 42  
 25 <212> TYPE: PRT  
 26 <213> ORGANISM: Homo sapiens  
 28 <220> FEATURE:  
 29 <223> OTHER INFORMATION: human Abeta42 beta-amyloid peptide  
 31 <400> SEQUENCE: 1  
 32 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
 33 1 5 10 15  
 35 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
 36 20 25 30  
 38 Gly Leu Met Val Gly Gly Val Val Ile Ala  
 39 35 40  
 42 <210> SEQ ID NO: 2  
 43 <211> LENGTH: 13  
 44 <212> TYPE: PRT  
 45 <213> ORGANISM: Artificial Sequence  
 47 <220> FEATURE:  
 48 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta1-12  
 49 peptide with carboxyl terminal Cys residue  
 50 inserted  
 52 <400> SEQUENCE: 2  
 53 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys  
 54 1 5 10  
 57 <210> SEQ ID NO: 3  
 58 <211> LENGTH: 6  
 59 <212> TYPE: PRT  
 60 <213> ORGANISM: Artificial Sequence  
 62 <220> FEATURE:  
 63 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta1-5  
 64 peptide with carboxyl terminal Cys residue  
 65 inserted  
 67 <400> SEQUENCE: 3  
 68 Asp Ala Glu Phe Arg Cys  
 69 1 5

ENTERED

*Entered from computer CRP, converted in Paper 3*

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/825,242

DATE: 04/25/2001

TIME: 13:49:23

Input Set : N:\Crf3\RULE60\09825242.txt

Output Set: N:\CRF3\04252001\I825242.raw

```

72 <210> SEQ ID NO: 4
73 <211> LENGTH: 12
74 <212> TYPE: PRT
75 <213> ORGANISM: Artificial Sequence
77 <220> FEATURE:
78 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta33-42
79     peptide with carboxyl terminal Cys residue
80     inserted
82 <220> FEATURE:
83 <221> NAME/KEY: MOD_RES
84 <222> LOCATION: (2)
85 <223> OTHER INFORMATION: Xaa = amino hepatanoic acid
87 <400> SEQUENCE: 4
W--> 88 Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
89     1             5             10
92 <210> SEQ ID NO: 5
93 <211> LENGTH: 19
94 <212> TYPE: PRT
95 <213> ORGANISM: Artificial Sequence
97 <220> FEATURE:
98 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28
99     peptide with carboxyl terminal Cys residue
100     inserted and two added Gly residues
102 <220> FEATURE:
103 <221> NAME/KEY: MOD_RES
104 <222> LOCATION: (1)
105 <223> OTHER INFORMATION: Xaa = acetyl histidine
107 <400> SEQUENCE: 5
W--> 108 Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
109     1             5             10             15
111 Gly Gly Cys

```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/825,242

DATE: 04/25/2001

TIME: 13:49:24

Input Set : N:\Crf3\RULE60\09825242.txt

Output Set: N:\CRF3\04252001\I825242.raw

L:88 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4

L:108 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5